BioNTech(us:BNTX)
90.29
-0.85%
Updated on 2025-04-02
Open:92.27
Close:90.29
High:92.39
Low:87.61
Prev Close:91.06
Volume:1.14M
Turnover:102.95M
Turnover Ratio:0.48%
Shares:239.97M
MarketCap:21.67B
About BioNTech
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Company Name: BioNTech
Address: An der Goldgrube 12
Employees: 6133
Fiscar Year: 12-31
IPO Date: 2019-10-10
Website: http://www.biontech.de
CIK: 1776985
View all SEC Filings
About
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Address:An der Goldgrube 12
Website:http://www.biontech.de
Market Movers